Cagri+Tirz vs Cagri+Sema: Amylin Pairing Choice

Cagrilintide is the long-acting amylin analog that two of the most-discussed metabolic peptide combinations are built around: layered onto tirzepatide (cagri+tirz) and layered onto semaglutide (cagri+sema). Both are about adding the amylin pathway to an incretin backbone, but the backbones are different and the trial datasets are very uneven.

Research-context information only. Cagrilintide is an investigational drug not approved by the FDA. Tirzepatide and semaglutide are the active ingredients in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. The cagrilintide + tirzepatide combination has no published clinical trial data. The cagrilintide + semaglutide combination has Phase 3 data (REDEFINE 1) but is not yet FDA-approved as a finished combination product. Consult a licensed physician for personal medical decisions.

This comparison covers the mechanism, the trial evidence, and the open empirical questions. The short version: cagri+sema has Phase 3 data and is on a regulatory track; cagri+tirz has none and exists only as a research-vendor combination, even though the mechanistic case for it may be stronger.

What Each Compound Pair Targets

Cagri+Sema (investigational FDA-track product)

Cagrilintide activates the amylin receptor system (AMY1R/AMY3R, calcitonin receptor + RAMP1/RAMP3 heterodimers). Semaglutide activates the GLP-1 receptor. The combination targets:

Two non-overlapping receptor systems; partially distinct brain regions; both pathways slow gastric emptying via different mechanisms.

Cagri+Tirz (research-vendor combination)

Cagrilintide is the same. Tirzepatide is a dual GIP/GLP-1 agonist — it activates both GIP and GLP-1 receptors. The combination targets:

Three non-overlapping receptor systems; the GIP layer is what makes this combination mechanistically distinct from cagri+sema.

Trial Data: REDEFINE 1 vs Nothing

REDEFINE 1 (Cagri+Sema, Phase 3)

Garvey et al., NEJM 2025. Randomized 3,417 adults with overweight/obesity (without type 2 diabetes) to one of four arms over 68 weeks:

The headline numbers:

• The combination outperformed semaglutide alone by 6.6 percentage points (a 41% relative gain).
• The combination outperformed cagrilintide alone by 10.9 percentage points.
• The combination did not show a clear plateau by 68 weeks.

This is the cleanest evidence base for amylin layering on a GLP-1 backbone. The Frias 2023 Phase 2 trial in type 2 diabetes (Frias et al., Lancet 2023) showed similar additive benefit.

Cagri+Tirz: No Trial Data

No Phase 1, no Phase 2, no Phase 3. The combination exists in research-vendor catalogs because tirzepatide is widely sold as a research compound and cagrilintide is widely sold as a research compound — but no sponsor has run a registered trial of the combination.

The reason is commercial. Tirzepatide is Eli Lilly. Cagrilintide is Novo Nordisk. Neither company has incentive to develop the other's molecule into a combination product. Novo's investigational FDA-track combination pairs cagrilintide with their own GLP-1 (semaglutide). Lilly's investigational triple-agonist program pursues retatrutide as a stand-alone (not as part of a cagrilintide combination).

This means anyone using cagri+tirz is operating outside any published efficacy or safety dataset for the specific combination.

Mechanistic Case for Cagri+Tirz

The case for cagri+tirz being plausibly stronger than cagri+sema rests on what GIP adds.

GIP receptor activation (tirzepatide-specific):

• Enhanced insulin secretion in glucose-dependent fashion
• Improved fat metabolism in adipose tissue
• Possible nausea attenuation — tirzepatide trials have somewhat better GI tolerability than semaglutide trials at equivalent weight loss

If REDEFINE 1's 6.6 percentage-point gain came from layering amylin on a GLP-1-only backbone, the same layering on a GLP-1 + GIP backbone could plausibly produce a larger gain — three non-overlapping pathways instead of two, with GIP's lipid-handling and possible GI-tolerability benefits adding to the case.

The "could plausibly" is doing a lot of work. Without trial data, the claim that cagri+tirz produces more weight loss than cagri+sema is mechanistic prediction, not empirical evidence.

What Trial-Level Tolerability Looks Like

REDEFINE 1 tolerability for cagri+sema:

Pattern: layering cagrilintide on semaglutide produced modestly more GI events than semaglutide alone, but discontinuation was similar. The amylin pathway adds satiety more than nausea.

Tirzepatide monotherapy in SURMOUNT-1 had nausea rates of ~24-29% — somewhat lower than semaglutide at equivalent weight loss. If amylin layering on tirz follows the same pattern as on sema (modestly more GI events but similar discontinuation), the cagri+tirz tolerability is plausibly similar to cagri+sema, but this is unstudied.

Pricing and Availability

Research-vendor pricing for both combinations is similar — driven by the per-compound pricing of cagrilintide plus the chosen incretin. For cagri+sema sourcing, see Where to Buy Cagrilintide and Where to Buy Semaglutide. For cagri+tirz, see Where to Buy Tirzepatide.

Side-by-Side Summary

How to Decide (If You're Researching the Question)

The decision framework most-described in research-context references:

Choose cagri+sema if:

• You want a combination with Phase 3 trial evidence behind it
• You're prioritizing trial-data tolerability characterization
• You're tracking the FDA-track investigational product as a future commercial option
• The 6.6-percentage-point REDEFINE 1 gain is the relevant outcome metric

Choose cagri+tirz if:

• You're already established and tolerated on tirzepatide and want to layer amylin on the existing backbone
• You weight mechanistic argument (stronger incretin backbone + amylin) over trial-data argument (the combination Phase 3 data exists for)
• You accept the structural absence of combination-specific safety data

Avoid both if:

• You don't have a clear research-context for the combination
• Trial-grade safety data is non-negotiable
• A licensed physician hasn't reviewed the protocol

Neither combination is being marketed as a finished pharmaceutical product through normal channels. Both involve research-peptide sourcing, with all of the COA-verification and lot-quality questions that come with it.

What About Retatrutide?

Retatrutide is the triple-agonist (GLP-1/GIP/glucagon) that is currently in Phase 3. The reta+cagri stack (covered separately in our Retatrutide+Cagrilintide Stack guides) takes the same amylin-layering logic and applies it to a stronger backbone than tirzepatide. The same caveat applies: zero published combination trials.

The three-way comparison:

Cagri+Sema has the data. The other two have the mechanistic argument.

Related Reading

• Cagrilintide Peptide Page — Mechanism and vendor profile
• Cagrilintide Benefits — Standalone amylin pathway
• Cagrilintide vs Semaglutide — Single-compound head-to-head
• Tirzepatide Peptide Page — Dual GIP/GLP-1 backbone
• Semaglutide Peptide Page — GLP-1 backbone
• Tirzepatide vs Semaglutide — Choosing the incretin backbone
• Retatrutide+Cagrilintide Stack — Triple-agonist + amylin
• Retatrutide vs Tirzepatide — Picking the strongest incretin
• Best Cagrilintide Vendors — Vendor rankings

References

For educational and research purposes only. This is not medical advice. Cagrilintide is investigational; the cagrilintide+tirzepatide combination has no published clinical trial data; the cagrilintide+semaglutide combination has Phase 3 data but is not yet an FDA-approved finished product.